Ab Initio Pharma Listed as one of Australia’s Fastest Growing Companies.
Ab Initio is pleased to announce it has been listed in the Australia Financial Review as one of the fastest growing start-up companies in Australia, being ranked in the 2022 AFR Fast Starters List.
Ab Initio Pharma is a specialist pharmaceutical R&D and manufacturing company that develops innovative medicines for clients, taking new molecules from the bench through to full GMP manufacturing for clinical trials.
CEO, Dr Paul Young, said “Ab Initio was established out of an unmet need as a local contract research organisation (CRO) that could provide both specialist formulation and GMP manufacturing services. Australia has a wealth of innovative pharmaceutical and biomedical start-ups, however there was no company that could help these innovators take a new drug from the lab into the clinic. Ab Initio meets that gap in the market by providing high quality formulation and manufacturing support.
Dr Will Glover (COO & Head of Quality) and Dr Hui Xin Ong (YY) (CSO & Head of R&D) at Ab Initio’s GMP Headquarters & manufacturing plant in Camperdown Sydney
COO and Head of Quality, Dr Will Glover said “we identified a significant gap in the market, where research organisations would be developing new therapies that could really make a difference to the health of Australian’s, but had no way of getting them into the clinic safely. To address this, in 2021, we commenced construction of our state-of-the-art GMP manufacturing facility in partnership with Sydney Local Health District. The Facility was completed in 2022 and was licensed for GMP production by the TGA in Q4 this year.
CSO, Dr Hui-Xin Ong said “with the completion of our manufacturing facility in Camperdown and tight integration with our R&D department, we now have an end-to-end solution for our clients. Our R&D team are able to take a new molecule, develop it into a formulation and transfer it to our factory for production. Ab Initio develops a wide variety of products for clients and is licensed to manufacture numerous dosage forms and drug classes as well has having a core speciality in respiratory and nasal product development.
Dr Young, said “ it is a great honour for Ab Initio to be listed in the AFR Fast 100 It is a testament to the hard work and dedication of the Ab Initio team that we have achieved so much over such a short period of time.”
Ab Initio was established as a spin-off from the University of Sydney in partnership with Sydney Local Health District and the peak industry body, ARCS. The company has grown rapidly to 20 staff since its operations commenced in 2020 supporting pharmaceutical product development for clients globally. The Australian Financial Review ranked Ab Initio 26th in the Fast Starters List, across all industry sectors ,with a 409% CAGR over the its first 2 years of operation.
